We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Court Upholds Amgen's Epogen Patents in Suit Against TKT, Aventis
Court Upholds Amgen's Epogen Patents in Suit Against TKT, Aventis
August 8, 2006
A federal appeals court has affirmed a lower court decision that an anemia drug co-developed by Aventis Pharmaceuticals and Transkaryotic Therapies (TKT) infringes on Amgen’s patents for its anemia drug Epogen.